SPOTLIGHT -
EP. 1: Introduction: Therapeutic Advances in mCRPC
EP. 2: AUA Castration-Resistant Prostate Cancer Guidelines
EP. 3: NCCN and AUA Prostate Cancer Guidelines
EP. 4: Role of Imaging in M0 CRPC
EP. 5: Preventing SREs in Prostate Cancer
EP. 6: Antiandrogen Monotherapy for mCRPC
EP. 7: Prognostic Biomarker Tests for Prostate Cancer
EP. 8: Biopsy, Biomarkers, and Imaging in Prostate Cancer
EP. 9: Biomarkers in the Management of Prostate Cancer
EP. 10: Evolution of Treatment for mCRPC
EP. 11: Multidisciplinary Approach to mCRPC Treatment
EP. 12: Treating Symptomatic Bone Metastatic CRPC
EP. 13: Oral Hormonal Agents for mCRPC
EP. 14: Treating mCRPC with Newer Hormonal Agents
EP. 15: Antiandrogens-Differences and Sequencing
EP. 16: Radium-223: Treatment Considerations
EP. 17: Sipuleucel-T in Castration-Resistant Prostate Cancer
EP. 18: Treatment Advances in Metastatic CRPC
EP. 19: SREs, Risk Stratification, and Agents in Development
EP. 20: Role of Nurses and Other Care Providers
EP. 21: Role of Urologists in Advanced Prostate Cancer Clinics
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
